Tender Details

Country: Belgium
Summary: Pharmaceutical Specialties Based on Eculizumab and Ravulizumab
BET Ref No: 123855588
Deadline: 18 Sep 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 508646-2025
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
New patients will be subject to this public market, patients currently under treatment must not be changed. The doctor will keep the possibility of using the molecule best suited to the patient's needs.
Pharmaceutical specialty based on Eculizumab or Ravulizumab
The drug must be available in 10mg/ml or in 100mg/ml, be reimbursed in Belgium at the opening of offers and have the following indications at least:
-Hemoglobinuria paroxysical night (HPN)
-ymolytic and atypical hemolytic and uremic (shua)
Based pharmaceutical specialty of Eculizumab or Ravulizumab
The drug must be available in 10mg/ml or 100mg/ml, be reimbursed in Belgium when the offers are opened and have at least the following indications:
-the -general acquired myasthenia refractory (MAG)
Ravulizumab pharmaceutical specialty
THE drug must be available in 100mg/ml, 3ml and 11ml and have at least
following indications:
-Maladie of the spectrum of optical neuromyelitis (NMOSD)
Doc Title: pharmaceutical specialties based on Eculizumab and Ravulizumab
Type contract: supplies
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Pharmaceutical Specialties Based on Eculizumab and Ravulizumab - Belgium Tender

The HEALTHCARE PUBLIC PROCUREMENT (HECAPP), a Government sector organization in Belgium, has announced a new tender for Pharmaceutical Specialties Based on Eculizumab and Ravulizumab. This tender is published on BelgiumTenders under BET Ref No: 123855588 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-18.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.